In The Lancet, Helen Strongman and colleagues 5 aimed to identify the long-term risk of cardiovascular disease in cancer survivors by use of primary care, hospital, and cancer registry data within the UK Clinical Practice Research Datalink. With these linked data, the authors were able to identify 108 215 cancer survivors and 523 541 controls for their main analyses. Of the cancer survivors, 51 541 (47·6%) were men and 56 674 (52·4%) were women; of the controls, 245 760 (46·9%) were men and 277 781 (53·1%) were women; and both survivors and controls had a median age of 67 years (IQR 58-76). Strongman and colleagues observed an increased risk of heart failure or cardiomyopathy in survivors of ten of 20 site-specific cancers compared with that of controls, including haematological (adjusted hazard ratio [HR] 1·94, 95% CI 1·66-2·25, with non-Hodgkin lymphoma; 1·77, 1·50-2·09, with leukaemia; and 3·29, 2·59-4·18, with multiple myeloma), oesophageal (1·96, 1·46-2·64), lung (1·82, 1·52-2·17), kidney (1·73, 1·38-2·17), and ovarian (1·59, 1·19-2·12). The authors also found an increased risk of thromboembolism in 18 of 20 of site-specific cancers, with adjusted HRs ranging from 1·72 (1·57-1·89) in patients after prostrate cancer to 9·72 (5·50-17·18) after pancreatic cancer, as well as increases in the risk of arrhythmia, pericarditis, coronary artery disease, stroke, and valvular heart disease for multiple other cancers.
Although these risks were seen primarily in patients who received chemotherapy, these data are consistent with previous data reported by Armenian and colleagues, 2 who looked at the risk of cardiovascular disease in a cohort of 36 232 cancer survivors in the Kaiser Permanente Southern California registry. Within Armenian and colleagues's study, as well as in the Long Island Breast Cancer cohort, 6 the risk of cardiovascular events in breast cancer survivors increased and surpassed that of age-matched controls. Armenian and colleagues 2 also found an increase in cardiovascular events in survivors of Hodgkin lymphoma, lung cancer, and multiple myeloma compared with that of controls. The analysis by Strongman and colleagues is limited by the fact that they use registry data that do not provide details of cancer treatments, including specific chemotherapies, chemotherapy doses, and radiation doses and fields. Additionally, the dataset does not have granular details on other cardiovascular risk factors including hyperlipidaemia, diet, alcohol intake, exercise, age of menopause, and family history of cardiovascular disease, which are all well known risk factors for cardiovascular disease. Despite these limitations, the size and breadth of the linked data source allowed for enough data and statistical power to do a comprehensive analysis of longterm cardiovascular risk in survivors of 20 site-specific cancers. The study by Strongman and colleagues again shows that cancer therapies, particularly chemotherapy, play a prominent role in cardiovascular risk, a risk that might be similar to that of tobacco use and increased body-mass index.
In clinical practice, the risk of cardiovascular events has been estimated with risk prediction tools such as the Framingham risk prediction score 7 and the Pooled Cohort Equations. 8 These tools, used to identify individuals at high risk of developing cardiovascular disease in the short-to-medium term, do not include cancer as one of the risk factors. In survivors of childhood cancer, Chow and colleagues 9, 10 showed an increased risk of cardiovascular events compared with that of controls who had not been diagnosed with cancer, with a clear demonstration that the Framingham risk score was not adequate in predicting risk of future cardiovascular events, such as heart failure and myocardial infarction, for these patients. Similar findings have been shown in small studies of breast cancer 11 and testicular cancer 12 survivors. These studies and the work of Strongman and colleagues make a strong case for research into whether the inclusion of cancer in these risk prediction tools, beyond the traditional risk factors for the prediction of cardiovascular disease risk, would add incremental value in the general population. In the meantime, clinicians should account for cancer, and especially chemotherapy, as a risk factor for cardiovascular disease when discerning individual patient risks to guide preventive interventions.
